Biotech Firm Clears Major U.S. Trading Hurdle
Source: Streetwise Reports (07/18/2025)
Rakovina Therapeutics Inc. (RKV:TSX.V) just gained DTC eligibility, opening the door for faster U.S. trades and broader investor access. With AI-driven cancer drugs in development, analysts are taking notice. Read more to find out why.
read more >
Biotech Partnership to Revolutionize Diabetes Treatment
Source: Streetwise Reports (07/15/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces a collaborative research agreement with Eledon Pharmaceuticals Inc. to assess Eledon's immunosuppressive drug in Sernova's ongoing trials of its cell pouch biohybrid organ for patients with Type 1 diabetes (T1D).
read more >
AI Healthtech Firm Partners with EngageWell and CVS Health Foundation on NYC Senior Care Initiative
Source: Streetwise Reports (07/14/2025)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launches virtual screening for older adults in NYC, backed by US$1M from CVS Health Foundation, as it scales AI tools and patient reach. Read more about how this initiative is helping expand access to care and driving growth in virtual health innovation.
read more >
Biotech Enters Agreement with Co. Behind Tegoprubart
Source: Dr. Joseph Pantginis (07/14/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report.
read more >
Biopharma Firm Assembles Elite AI Cancer Team
Source: Streetwise Reports (07/11/2025)
Rakovina Therapeutics Inc. (RKV:TSX.V) strengthens its AI-driven cancer program with a world-class advisory board and breakthrough drug discovery platforms. Read more about how Rakovina's expert-backed strategy and proprietary platforms support next-gen oncology drug development and potential licensing deals.
read more >